However, another study indicated that colorectal cancer patients with a 2.3~10% KRAS mutant allele burden in tumor tissue might be resistant to anti-EGFR therapy, and suggested that a >2.3% MAF detected in tumor tissue should be considered positive for KRAS mutation [5]. The gene discussed is KRAS; the disease is neoplasm.